These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37012934)

  • 1. Drug-Induced Reaction With Eosinophilia and Systemic Symptoms: A Review.
    Alotaibi M
    Cureus; 2023 Mar; 15(3):e35701. PubMed ID: 37012934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.
    Mustafa SS; Ostrov D; Yerly D
    Curr Allergy Asthma Rep; 2018 Mar; 18(4):26. PubMed ID: 29574562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cicatrizing Conjunctivitis in a Patient Diagnosed With Drug Reaction With Eosinophilia and Systemic Symptoms/Drug-Induced Hypersensitivity Syndrome but With Features of Stevens-Johnson Syndrome.
    Bohm KJ; Ciralsky JB; Harp JL; Bajaj S; Sippel KC
    Cornea; 2016 Jun; 35(6):888-91. PubMed ID: 27078005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features and prognostic factors of severe cutaneous adverse drug reactions: A single-center retrospective study of 209 cases in China.
    Deng M; Su Y; Wu R; Li S; Tang G; Kuang Q; Luo X; Zhu Y; Shen W
    Int Immunopharmacol; 2023 Jan; 114():109530. PubMed ID: 36508915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe cutaneous adverse reaction associated with antiseizure medications: Diagnosis, management, and prevention.
    Brandt C; McGuire L; Uetrecht J
    Epilepsy Behav; 2021 Apr; 117():107844. PubMed ID: 33639435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis).
    Owen CE; Jones JM
    Med Clin North Am; 2021 Jul; 105(4):577-597. PubMed ID: 34059239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of Life of Drug Reaction with Eosinophilia and Systemic Symptom (DRESS) and Stevens-Johnson Syndrome (SJS) and/or Toxic Epidermal Necrolysis (TEN) Patients.
    Perwitasari DA; Febriana SA; Tristiana RS
    Patient Prefer Adherence; 2021; 15():329-335. PubMed ID: 33623374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe delayed skin reactions related to drugs in the paediatric age group: A review of the subject by way of three cases (Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS).
    Belver MT; Michavila A; Bobolea I; Feito M; Bellón T; Quirce S
    Allergol Immunopathol (Madr); 2016; 44(1):83-95. PubMed ID: 26089185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug reaction with eosinophilia and systemic symptoms].
    Tehrany YA; Laffitte E; Grosgurin O; Spoerl D
    Rev Med Suisse; 2016 Apr; 12(513):684-6, 688-90. PubMed ID: 27197323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe Cutaneous Adverse Reactions: A Single-Center Retrospective Study of 173 Patients in China.
    Xu Z; Shen J; Yang Y; Yuan R; Xiang LF; Zhang C
    Ann Dermatol; 2019 Oct; 31(5):545-554. PubMed ID: 33911647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ivermectin-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.
    Kerneuzet I; Blind E; Darrieux L; Moreau S; Safa G
    JAAD Case Rep; 2018 Jul; 4(6):524-527. PubMed ID: 30023418
    [No Abstract]   [Full Text] [Related]  

  • 12. Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms.
    Dao RL; Su SC; Chung WH
    Asia Pac Allergy; 2015 Apr; 5(2):59-67. PubMed ID: 25938070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population.
    Ramírez E; Bellón T; Tong HY; Borobia AM; de Abajo FJ; Lerma V; Moreno Hidalgo MA; Castañer JL; Cabañas R; Fiandor A; González-Ramos J; Herranz P; Cachafeiro L; González-Herrada C; González O; Aramburu JA; Laosa O; Hernández R; Carcas AJ; Frías J
    Pharmacol Res; 2017 Jan; 115():168-178. PubMed ID: 27888155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features and prognostic factors in severe cutaneous drug reactions.
    Yang MS; Kang MG; Jung JW; Song WJ; Kang HR; Cho SH; Min KU
    Int Arch Allergy Immunol; 2013; 162(4):346-54. PubMed ID: 24193402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking.
    Walsh SA; Creamer D
    Clin Exp Dermatol; 2011 Jan; 36(1):6-11. PubMed ID: 21143513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of liver injury in drug-induced systemic hypersensitivity reactions.
    Lee T; Lee YS; Yoon SY; Kim S; Bae YJ; Kwon HS; Cho YS; Moon HB; Kim TB
    J Am Acad Dermatol; 2013 Sep; 69(3):407-15. PubMed ID: 23632341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Individual Case Safety Reports of Severe Cutaneous Adverse Reactions in Korea.
    Kang MG; Sohn KH; Kang DY; Park HK; Yang MS; Lee JY; Kang HR
    Yonsei Med J; 2019 Feb; 60(2):208-215. PubMed ID: 30666843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug rash with eosinophilia and systemic symptoms vs toxic epidermal necrolysis: the dilemma of classification.
    Wolf R; Matz H; Marcos B; Orion E
    Clin Dermatol; 2005; 23(3):311-4. PubMed ID: 15896547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interferon-γ-induced protein 10/CXCR3 axis is associated with human herpesvirus-6 reactivation and the development of sequelae in drug reaction with eosinophilia and systemic symptoms.
    Yang CW; Cho YT; Hsieh YC; Hsu SH; Chen KL; Chu CY
    Br J Dermatol; 2020 Nov; 183(5):909-919. PubMed ID: 32037509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe Drug Hypersensitivity Reactions: Clinical Pattern, Diagnosis, Etiology and Therapeutic Options.
    Paulmann M; Mockenhaupt M
    Curr Pharm Des; 2016; 22(45):6852-6861. PubMed ID: 27779083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.